ABR suggested buying CVS Health stock on July 18, 2025.
2 reports, 1 independent
Updated Jul 18
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ABR suggested buying CVS Health stock on July 18, 2025.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
ABR
Czech company
-
CVS Health
company
Related events
- HSBC restated its 'hold' rating on CVS Health, while Manufacturers Life Insurance Company increased its stake in the company's shares.
- Truist Financial raised its target price and gave a 'buy' rating for CVS Health.
- CVS Health is expanding its drug offerings to include Eli Lilly's Zepbound and Novo Nordisk's Wegovy, while also considering an investment in Roche.
- Larry Robbins sold CVS Health shares, and Fifth Third Bancorp lifted its position in CVS Health stock, both disclosed to the SEC.
- CVS Health and Invesco were identified as top dividend stocks in a 2025 index.
Coverage
Newest first; wire copies grouped- ZacksIs CVS Health (CVS) a Buy as Wall Street Analysts Look Optimistic? The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Me
- Unknown outlet